SCHEMBL2653162

SCHEMBL2653162

CCCCc1ccc(NC(=O)Oc2ccccc2)c(S(N)(=O)=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.47
CA2 P00918 5/20 0.45
KDM4E B2RXH2 1/20 0.45
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
BLM P54132 1/20 0.45
SLC12A2 P55011 1/20 0.45
HIF1A Q16665 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HSD17B10 Q99714 1/20 0.45
FAAH O00519 6/20 0.45
RAB9A P51151 1/20 0.44
CA1 P00915 3/20 0.44
CA12 O43570 2/20 0.44
CA9 Q16790 2/20 0.44
RAD51 Q06609 1/20 0.42
AQP1 P29972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10489857 0.82 METAP2 (0.59) METAP2KDM4EFAAH
SCHEMBL28746968 0.81 CA12 (0.48) METAP2CA2ALDH1A1HPGDFAAH
SCHEMBL30361520 0.79 FAAH (0.52) FAAHRAB9A
SCHEMBL28261566 0.79 FAAH (0.49) FAAHRAB9A
SCHEMBL28698992 0.77 CA1 (0.56) CA2CA1CA12CA9
SCHEMBL10112975 0.76 FAAH (0.67) KDM4EALDH1A1LMNAHPGDFAAH
SCHEMBL10489769 0.75 METAP2 (0.57) METAP2KDM4EALDH1A1HPGDRAB9A
SCHEMBL9126282 0.74 FAAH (0.44) FAAHRAB9A
SCHEMBL29233073 0.74 RAB9A (0.74) ALDH1A1LMNAHPGDFAAHRAB9A
SCHEMBL7339580 0.72 FAAH (0.72) KDM4EALDH1A1LMNAHPGDFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed
EP-1183229-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-03-06 EP disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 WO disclosed